| 000 | 01320 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250514030517.0 | ||
| 264 | 0 | _c20020412 | |
| 008 | 200204s 0 0 eng d | ||
| 040 |
_aNLM _beng _cNLM |
||
| 245 | 0 | 0 |
_aHigh-dose lymphoablative therapy (HDLT) with or without autologous stem-cell rescue for treatment of severe autoimmune diseases. _h[electronic resource] |
| 260 |
_bTecnologica. MAP supplement. Blue Cross and Blue Shield Association. Medical Advisory Panel _cDec 2001 |
||
| 300 |
_a29-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntilymphocyte Serum _xadministration & dosage |
| 650 | 0 | 4 |
_aAutoimmune Diseases _xmortality |
| 650 | 0 | 4 | _aBlue Cross Blue Shield Insurance Plans |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aInsurance Coverage |
| 650 | 0 | 4 | _aTechnology Assessment, Biomedical |
| 650 | 0 | 4 | _aTransplantation, Autologous |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aUnited States Food and Drug Administration |
| 773 | 0 |
_tTecnologica. MAP supplement. Blue Cross and Blue Shield Association. Medical Advisory Panel _gp. 29-9 |
|
| 999 |
_c11838107 _d11838107 |
||